Advances in Aptamers

Syed, Muhammad Ali; Pervaiz, Saima

doi:10.1089/oli.2010.0234

Cited by 78 publications

(72 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They are also stable during long-term storage and easy to transport at an ambient temperature. Similar to antibodies, aptamers can also be labeled with reporter molecules such as fluorescein, biotin, and digoxigenin, which increases their applicability for further applications (39)(40)(41)(42)(43)(44)(45). DNA and RNA aptamers have shown similar function and performance in terms of affinity and specificity (46).…”

Section: Discussionmentioning

confidence: 99%

Neutralizing DNA Aptamers against Swine Influenza H3N2 Viruses

et al. 2013

View full text Add to dashboard Cite

e Triple reassortant influenza A viruses (IAVs) of swine, particularly the North American H3N2 subtype, circulate in swine herds and may reassort and result in the emergence of novel zoonotic strains. Current diagnostic tools rely on isolation of the viruses, followed by serotyping by hemagglutination or genome sequencing, both of which can be expensive and time-consuming. Thus, novel subtype-specific ligands and methods are needed for rapid testing and subtyping of IAVs in the field. To address this need, we selected DNA aptamers against the recombinant HA protein from swine IAV H3 cluster IV using systematic evolution of ligands by exponential enrichment (SELEX). Four candidate aptamers (HA68, HA7, HA2a, and HA2b) were identified and characterized. The dissociation constants (K d ) of aptamers HA68, HA7, HA2a, and HA2b against recombinant H3 protein were 7.1, 22.3, 16.0, and 3.7 nM, respectively. The binding site of HA68 to H3 was identified to be between nucleotide residues 8 and 40. All aptamers inhibited H3 hemagglutination. HA68 was highly specific to all four lineages within the North American H3N2 subtype. Further, the other three aptamers specifically identified live viruses belonging to the phylogenetic clusters I, II/III, and IV especially the virus that closely related to the recent H3N2 variant (H3N2v). Aptamer HA68 was also able to bind and detect H3N2v isolated from recent human cases. In conclusion, we provide subtype-specific aptamers against H3N2 IAVs of swine that can now be used in rapid detection and typing protocols for field applications.

show abstract

Section: Discussionmentioning

confidence: 99%

Neutralizing DNA Aptamers against Swine Influenza H3N2 Viruses

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Table 2 lists additional aptamers that are in various phases of clinical development. Readers are referred to excellent recent reviews that provide a more in depth discussion of this new platform and its therapeutic potential (20)(21)(22)(23)(24).…”

Section: Oligonucleotide Aptamer Ligandsmentioning

confidence: 99%

Use of Oligonucleotide Aptamer Ligands to Modulate the Function of Immune Receptors

Gilboa

McNamara

Pastor

2013

Clinical Cancer Research

View full text Add to dashboard Cite

The paucity of costimulation at the tumor site compromises the ability of tumor-specific T cells to eliminate the tumor. The recent U.S. Food and Drug Administration approval of ipilumimab, an antibody that blocks the inhibitory action of CTLA-4, and clinical trials targeting 4-1BB and PD-1 or PD-L1, have underscored the therapeutic potential of using immunomodulatory antibodies to stimulate protective immunity in human patients. Nonetheless, systemic administration of immunomodulatory antibodies has been associated with dose-limiting autoimmune pathologies, conceivably reflecting also the activation of resident autoreactive T cells. Arguably, targeting immunomodulatory ligands to the disseminated tumor lesions of the patient would reduce such drug-associated toxicities. We have recently developed a new class of inhibitory (CTLA-4) and agonistic (4-1BB and OX-40) ligands composed of short oligonucleotide (ODN) aptamers that exhibited bioactivities comparable or superior to that of antibodies. To reduce toxicity, the immunomodulatory aptamers were targeted to the tumor by conjugation to a second aptamer that bound to a product expressed on the surface of the tumor cell, the targeting aptamer, generating a bispecific aptamer conjugate analogous to bispecific antibodies. In a proof-of-concept study in mice, we have shown that an agonistic 4-1BB-binding aptamer conjugated to a prostate-specific membrane antigen (PSMA)-binding aptamer led to the inhibition of PSMA-expressing tumors, was more effective than, and synergized with, vaccination, and exhibited a superior therapeutic index compared with nontargeted costimulation with 4-1BB antibodies or 4-1BB aptamers. The cell-free chemically synthesized ODN aptamers offer significant advantages over antibodies in terms of synthesis, cost, as well as conjugation chemistry needed to generate bispecific ligand fusions.

show abstract

“…Incorporation of modified nucleotides during SELEX requires the use of mutant T7 polymerases that will utilize these NTPs by in vitro transcription. These modifications minimize degradation of RNA oligonucleotides by nucleases (Bunka, Platonova et al 2010;Syed and Pervaiz 2010).…”

Section: Selex (Systematic Evolution Of Ligands By Exponential Enrichmentioning

confidence: 99%

“…One aptamer is already being used as a therapeutic agent The small size of aptamers is advantageous for accessing their targets in vivo, but this also results in rapid renal clearance. To extend retention time in the system, aptamers are conjugated with PEG to increase molecular weight (Syed and Pervaiz 2010).…”

Section: Application Of Aptamersmentioning

confidence: 99%

Imaging gene expression in real-time using aptamers

Shin

2012

View full text Add to dashboard Cite

Advances in Aptamers

Cited by 78 publications

References 80 publications

Neutralizing DNA Aptamers against Swine Influenza H3N2 Viruses

Neutralizing DNA Aptamers against Swine Influenza H3N2 Viruses

Use of Oligonucleotide Aptamer Ligands to Modulate the Function of Immune Receptors

Imaging gene expression in real-time using aptamers

Contact Info

Product

Resources

About